Ixekizumab for Psoriatic Arthritis: Follow-Up Safety Data from SPIRIT
Ixekizumab demonstrated favorable tolerability and safety, in line with previous reports, for treatment of psoriatic arthritis, according to a large safety analysis of the...
Psoriatic Arthritis Worsens QoL in Patients With Psoriasis
People with psoriasis/psoriatic arthritis (PsA) have a decreased ability to participate in social roles and activities and more depressive symptoms than those with psoriasis...
Rheumatology Round-up: Six-Year Outcomes of ACL Revision Surgery; and More
RA Predictors ID'd in Undifferentiated Large Joint Arthritis
Autoantibody positivity and subclinical synovitis are independent predictors of rheumatoid arthritis (RA) among patients presenting with undifferentiated...
Rheum Round-up: Oral Microbiome Different in RA, Biologics Comparison, and more
A recent study observed differences in oral microbiome between patients with early rheumatoid arthritis (RA) or at high-risk of the disease compared to controls....
Ustekinumab Versus Other Biologics in Psoriatic Disease: Which Medications Increase Risk for Infection?
In a recent study, researchers compared ustekinumab versus other biologics and apremilast for risk of serious infection requiring hospitalization among patients with psoriasis (PsO)...
Patient Characteristics at Diagnosis May Predict 10-Year Psoriasis Disease Course
Early identification of certain patient factors may predict long-term outcomes in psoriasis, according to a study. Between 2001 and 2005, patients were enrolled in the...
Golimumab Treatment Retention Comparison: RA, AxSpA, and PsA
A study retrospectively compared rates of treatment retention with golimumab among patients with rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), and psoriatic arthritis (PsA). “Retention of...
